Expanding treatment options in NSCLC patients with rare mutations: ALK, ROS1, MET, BRAF
Expanding treatment options in NSCLC patients wi
Expanding treatment options in NSCLC patients wi
Immunotherapy: updates on clinical trials and ot
Preface – ASCO 2016 Paul A. Bunn Jr., MD, FA